Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
111 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Growth Hormone Deficiency - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Growth Hormone Deficiency - Pipeline Review, H2 2014', provides an overview of the Growth Hormone Deficiency's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Growth Hormone Deficiency pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Growth Hormone Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Growth Hormone Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Growth Hormone Deficiency Overview 9 Therapeutics Development 10 Pipeline Products for Growth Hormone Deficiency - Overview 10 Pipeline Products for Growth Hormone Deficiency - Comparative Analysis 11 Growth Hormone Deficiency - Therapeutics under Development by Companies 12 Growth Hormone Deficiency - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Growth Hormone Deficiency - Products under Development by Companies 18 Growth Hormone Deficiency - Companies Involved in Therapeutics Development 19 Teva Pharmaceutical Industries Limited 19 OPKO Health, Inc. 20 Access Pharmaceuticals, Inc. 21 AEterna Zentaris Inc. 22 Flamel Technologies S.A. 23 Emisphere Technologies, Inc. 24 HanAll Biopharma Co., Ltd. 25 LG Life Sciences, Ltd. 26 CJ CheilJedang Corp. 27 Critical Pharmaceuticals Limited 28 Aileron Therapeutics, Inc. 29 Ambrx, Inc. 30 Braasch Biotech LLC 31 Versartis, Inc. 32 Genexine, Inc. 33 Bolder Biotechnology, Inc. 34 Ascendis Pharma A/S 35 Pfenex Inc. 36 Delpor, Inc. 37 Inbiopro Solutions Pvt. Ltd. 38 Hanmi Pharmaceuticals, Co. Ltd. 39 Biogenomics Limited 40 XL-protein GmbH 41 Growth Hormone Deficiency - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Target 43 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 macimorelin acetate - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 somatropin SR - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 MOD-4023 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 somatropin - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 MOD-4023 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ARX-201 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 ACP-001 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 HM-10560A - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 albutropin - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 SYN-20100504RU - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 somatropin - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 GXH-9 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 somatropin - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 HL-032 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 somatropin - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 ALRN-5281 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 CJ-40002 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 somatropin biobetter - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 somatropin biobetter - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 CP-016 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 CobOral hGH - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 BBT-031 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 somatropin biosimilar - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 IBPB-003HH - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 somatropin biosimilar - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Vaccine For Growth Hormone Deficiencies - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 XL-020 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 somatropin - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Growth Hormone Deficiency - Recent Pipeline Updates 88 Growth Hormone Deficiency - Dormant Projects 100 Growth Hormone Deficiency - Discontinued Products 101 Growth Hormone Deficiency - Product Development Milestones 102 Featured News & Press Releases 102 Jun 30, 2014: Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317 102 Jun 27, 2014: OPKO Granted Patent from European Patent Office for Lagova 102 Jun 25, 2014: Strong Data from Lagova Phase II Clinical Study Presented during Webcast 103 Jun 23, 2014: OPKO Announces Positive Interim Six-Month Lagova (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder 104 Jun 23, 2014: Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results 105 Jun 09, 2014: Versartis to Hold Conference Call to Discuss Six Month VRS-317 Phase 2a VERTICAL Clinical Trial Results 106 May 20, 2014: Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to Be Presented at the 2014 ICE/ENDO Meeting 107 May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 107 May 19, 2014: Versartis Selects Comprehend Systems 108 Apr 08, 2014: Critical Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Intranasal Growth Hormone 108 Appendix 110 Methodology 110 Coverage 110 Secondary Research 110 Primary Research 110 Expert Panel Validation 110 Contact Us 111 Disclaimer 111
List of Tables Number of Products under Development for Growth Hormone Deficiency, H2 2014 10 Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Development by Companies, H2 2014 (Contd..1) 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Products under Development by Companies, H2 2014 18 Growth Hormone Deficiency - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 19 Growth Hormone Deficiency - Pipeline by OPKO Health, Inc., H2 2014 20 Growth Hormone Deficiency - Pipeline by Access Pharmaceuticals, Inc., H2 2014 21 Growth Hormone Deficiency - Pipeline by AEterna Zentaris Inc., H2 2014 22 Growth Hormone Deficiency - Pipeline by Flamel Technologies S.A., H2 2014 23 Growth Hormone Deficiency - Pipeline by Emisphere Technologies, Inc., H2 2014 24 Growth Hormone Deficiency - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 25 Growth Hormone Deficiency - Pipeline by LG Life Sciences, Ltd., H2 2014 26 Growth Hormone Deficiency - Pipeline by CJ CheilJedang Corp., H2 2014 27 Growth Hormone Deficiency - Pipeline by Critical Pharmaceuticals Limited, H2 2014 28 Growth Hormone Deficiency - Pipeline by Aileron Therapeutics, Inc., H2 2014 29 Growth Hormone Deficiency - Pipeline by Ambrx, Inc., H2 2014 30 Growth Hormone Deficiency - Pipeline by Braasch Biotech LLC, H2 2014 31 Growth Hormone Deficiency - Pipeline by Versartis, Inc., H2 2014 32 Growth Hormone Deficiency - Pipeline by Genexine, Inc., H2 2014 33 Growth Hormone Deficiency - Pipeline by Bolder Biotechnology, Inc., H2 2014 34 Growth Hormone Deficiency - Pipeline by Ascendis Pharma A/S, H2 2014 35 Growth Hormone Deficiency - Pipeline by Pfenex Inc., H2 2014 36 Growth Hormone Deficiency - Pipeline by Delpor, Inc., H2 2014 37 Growth Hormone Deficiency - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 38 Growth Hormone Deficiency - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 39 Growth Hormone Deficiency - Pipeline by Biogenomics Limited, H2 2014 40 Growth Hormone Deficiency - Pipeline by XL-protein GmbH, H2 2014 41 Assessment by Monotherapy Products, H2 2014 42 Number of Products by Stage and Target, H2 2014 44 Number of Products by Stage and Mechanism of Action, H2 2014 46 Number of Products by Stage and Route of Administration, H2 2014 48 Number of Products by Stage and Molecule Type, H2 2014 50 Growth Hormone Deficiency Therapeutics - Recent Pipeline Updates, H2 2014 88 Growth Hormone Deficiency - Dormant Projects, H2 2014 100 Growth Hormone Deficiency - Discontinued Products, H2 2014 101
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
